Phase III trial of sunitinib (Su) versus sorafenib (So) in advanced hepatocellular carcinoma (HCC)

被引：75

作者：

Cheng, A.

Kang, Y.

Lin, D.

Park, J.

Kudo, M.

Qin, S.

Omata, M.

Lowenthal, S. W. Pitman

Lanzalone, S.

Yang, L.

Lechuga, M.

Raymond, E.

机构：

[1] Natl Taiwan Univ Hosp, Taipei, Taiwan

[2] Asan Med Ctr, Seoul, South Korea

[3] Chang Gung Mem Hosp, Taoyuan, Taiwan

[4] Chang Gung Univ, Taoyuan, Taiwan

[5] Natl Canc Ctr, Ctr Liver Canc, Goyang, South Korea

[6] Kinki Univ, Fac Med, Osaka, Japan

[7] Nanjing Bayi Hosp, Nanjing, Jiangsu, Peoples R China

[8] Yamanashi Prefecture Cent Hosp, Kofu, Yamanashi, Japan

[9] Pfizer Oncol, New York, NY USA

[10] Pfizer Italia Srl, Pfizer Oncol, Milan, Italy

[11] Pfizer Oncol, La Jolla, CA USA

[12] Beaujon Univ Hosp, Clichy, France

来源：

关键词：

D O I：

10.1200/jco.2011.29.15_suppl.4000

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

4000

引用

页数：1